Study on the mechanism of miR-515-5p enhanced the cisplatin sensitivity of NSCLC A549/DDP cells via targeting RING1

doi:10.3877/cma.j.issn.1674-6902.2021.05.003

Abstract

Abstract:

Objective

To investigate the effect and mechanism of microRNA-515-5p (miR-515-5p) on the cisplatin sensitivity of non-small cell lung cancer (NSCLC).

Methods

The expression of miR-515-5p in BEAS-2B, A549 and A549/DDP cells was detected by real-time fluorescent quantitative PCR (RT-qPCR). A549/DDP cells were divided into NC group, miR-515-5p group, si-RING1 group and miR-515-5p inh+ si-RING1 group. CCK-8 assay was used to assess the proliferation of A549/DDP cells. WB was performed to measure the expression of RING1 and apoptosis related proteins. Dual luciferase reporter gene system was used to verify the targeting relationship between miR-515-5p and RING1.

Results

The expression of miR-515-5p in BEAS-2B, A549 and A549/DDP cells were (1.00±0.03), (0.61±0.03), (0.31±0.04), respectively. A549/DDP cells were transfected with miR-515-5p mimics, the OD₄₅₀ values of cells in NC group and miR-515-5p group at 24, 48, 72 and 96 h were (0.61±0.02), (0.52±0.02), (0.84±0.02), (0.68±0.04), (1.03±0.03), (0.79±0.04), (1.08±0.03), (0.86±0.04), respectively. The differences of those items were all statistically significant (all P<0.05). The expression of cleaved caspase-3, cleaved PARP and Bax in miR-515-5p group were significantly higher than those in NC group, and the expression of Bcl-2 were significantly lower than those in NC group. A549/DDP cells were transfected with si-RING1 and miR-515-5p inhibitor, the OD₄₅₀ values of cells in NC group, si-RING1 group and miR-515-5p inh+ si-RING1 group at 24, 48, 72 and 96 h were (0.63±0.02), (0.49±0.04), (0.58±0.03), (0.83±0.03), (0.62±0.05), (0.80±0.02), (1.05±0.04), (0.76±0.03), (1.02±0.04), (1.15±0.05), (0.86±0.03), (1.12±0.06), respectively. The differences of those items were all statistically significant (all P<0.05). The expression of cleaved caspase-3, cleaved PARP and Bax in si-RING1 group were significantly higher than those in NC group and miR-515-5p inh+ siRING1 group, and the expression of Bcl-2 were significantly lower than those in NC group and miR-515-5p inh+ siRING1 group.

Conclusion

miR-515-5p enhanced the cisplatin sensitivity of A549/DDP cells through targeting downregulate the expression of RING1.

Key words: MicroRNA-515-5p, Ring finger protein 1, Non-small cell lung cancer, Cisplatin sensitivity

Rui Xu, Yong Qian, Haiyan Zhang. Study on the mechanism of miR-515-5p enhanced the cisplatin sensitivity of NSCLC A549/DDP cells via targeting RING1[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 559-563.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2021.05.003

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2021/V14/I05/559

Figures/Tables 5

References 31

1	Yang B, Zheng D, Zeng U, et al. Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients[J]. J BUON, 2018, 23(4): 1077-1081.
2	Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance[J]. Oncogene, 2012, 31(15): 1869-1883.
3	肖丹，杜琴，贺斌峰，等. YAP调控肺癌A549/DDP细胞顺铂耐药性的机制分析[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(6): 697-701.
4	Rao C, Miao X, Zhao G, et al. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9[J]. Biomed Pharmacoth, 2019, 114: 108662.
5	Zhou H, Li J, Zhang Z, et al. RING1 and YY1 binding protein suppresses breast cancer growth and metastasis[J]. Int J Oncol, 2016, 49(6): 2442-2452.
6	Zhou Y, Wan C, Liu Y, et al. Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer[J]. Pathol Oncol Res, 2014, 20(3): 549-556.
7	Shen J, Li P, Shao X, et al. The E3 ligase RING1 targets p53 for degradation and promotes cancer cell proliferation and survival[J]. Cancer Res, 2018, 78(2): 359-371.
8	Xiong Y, Hu B, Wei L, et al. Upregulated expression of polycomb protein Ring1 contributes to poor prognosis and accelerated proliferation in human hepatocellular carcinoma[J]. Tumour Biol, 2015, 36(12): 9579-9588.
9	Hu B, Zhang H, Wang Z, et al. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4[J]. Cancer Biol Ther, 2017, 18(12): 974-983.
10	Xu G, Zhang Z, Zhang L, et al. miR-4326 promotes lung cancer cell proliferation through targeting tumor suppressor APC2[J]. Molecul Cellul Biochem, 2018, 443(1-2): 151-157.
11	Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method[J]. Methods, 2001, 25(4): 402-408.
12	Chen K, Abuduwufuer A, Zhang H, et al. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23(16): 6935-6943.
13	Guo J, Jin D, Wu Y, et al. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells[J]. EBioMedicine, 2018, 35: 204-221.
14	Li J H, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data[J]. Nucleic Acids Res, 2014, 42(Database issue): D92-D97.
15	Du L, Pertsemlidis A. microRNA regulation of cell viability and drug sensitivity in lung cancer[J]. Expert Opin Biol Ther, 2012, 12(9): 1221-1239.
16	Wang S, Li MY, Liu Y, et al. The role of microRNA in cisplatin resistance or sensitivity[J]. Expert Opin Ther Targets, 2020, 24(9): 885-897.
17	Lu X, Liu R, Wang M, et al. MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer[J]. Oncogene, 2019, 39(1): 234-247.
18	Rong F, Liu L, Zou C, et al. MALAT1 promotes cell tumorigenicity through regulating miR-515-5p/EEF2 axis in non-small cell lung cancer[J]. Cancer Manag Res, 2020, 12: 7691-7701.
19	Liu J, Eckert MA, Harada BT, et al. m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer[J]. Nature Cell Biol, 2018, 20(9): 1074-1083.
20	Van Leenders GJ, Dukers D, Hessels D, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features[J]. Eur Urol, 2007, 52(2): 455-463.
21	Yuan XW, Yan TQ, Tong H. Effect of miR-515-5p on proliferation and drug sensitivity of retinoblastoma cells[J]. Cancer Manag Res, 2020, 12: 12087-12098.
22	Zhong Y, Wang D, Ding Y, et al. Circular RNA circ_0032821 contributes to oxaliplatin (OXA) resistance of gastric cancer cells by regulating SOX9 via miR-515-5p[J]. Biotechnol Lett, 2021, 43(2): 339-351.
23	Han Y, Li F, Xie J, et al. PVT1 mediates cell proliferation, apoptosis and radioresistance in nasopharyngeal carcinoma through regulating miR-515-5p/PIK3CA axis[J]. Cancer Manag Res, 2020, 12: 10077-10090.
24	Qiao K, Ning S, Wan L, et al. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 418.
25	Wang D, Liu K, Chen E. LINC00511 promotes proliferation and invasion by sponging miR-515-5p in gastric cancer[J]. Cell Molecul Biol Lett, 2020, 25: 4.
26	Zhang Y, Shi Z, Li Z, et al. Circ_0057553/miR-515-5p regulates prostate cancer cell proliferation, apoptosis, migration, invasion and aerobic glycolysis by targeting YES1[J]. Onco Targets Ther, 2020, 13: 11289-11299.
27	Zhang X, Zhou J, Xue D, et al. MiR-515-5p acts as a tumor suppressor via targeting TRIP13 in prostate cancer[J]. Int J Biol Macromol, 2019, 129: 227-232.
28	Ni JS, Zheng H, Ou YL, et al. miR-515-5p suppresses HCC migration and invasion via targeting IL6/JAK/STAT3 pathway[J]. Surg Oncol, 2020, 34: 113-120.
29	Guo F, Li S, Guo C, et al. Circular RNA circMAGI3 accelerates the glycolysis of non-small cell lung cancer through miR-515-5p/HDGF[J]. Am J Transl Res, 2020, 12(7): 3953-3963.
30	Wang Y, Zhang Q. Long noncoding RNA MALAT1 knockdown inhibits proliferation, migration, and invasion and promotes apoptosis in non-small-cell lung cancer cells through regulating miR-515-3p/TRIM65 axis[J]. Cancer Biother Radiopharm, 2020, doi: 10.1089/cbr.2020.3730.
31	Li J, Tang Z, Wang H, et al. CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p[J]. Biomed Pharmacother, 2018, 97: 182-1188.

分　组	24 h	48 h	72 h	96 h
NC组	0.61±0.02	0.84±0.02	1.03±0.03	1.08±0.03
miR-515-5p组	0.52±0.02^a	0.68±0.04^a	0.79±0.04^a	0.86±0.04^a

分　组	24 h	48 h	72 h	96 h
NC组	0.61±0.02	0.84±0.02	1.03±0.03	1.08±0.03
miR-515-5p组	0.52±0.02^a	0.68±0.04^a	0.79±0.04^a	0.86±0.04^a

分　组	24 h	48 h	72 h	96 h
NC组	0.63±0.02	0.83±0.03	1.05±0.04	1.15±0.05
si-SING1组	0.49±0.04^a	0.62±0.05^a	0.76±0.03^a	0.86±0.03^a
miR-515-5p inh　+si-RING1组	0.58±0.03^b	0.80±0.02^b	1.02±0.04^b	1.12±0.06^b

分　组	24 h	48 h	72 h	96 h
NC组	0.63±0.02	0.83±0.03	1.05±0.04	1.15±0.05
si-SING1组	0.49±0.04^a	0.62±0.05^a	0.76±0.03^a	0.86±0.03^a
miR-515-5p inh　+si-RING1组	0.58±0.03^b	0.80±0.02^b	1.02±0.04^b	1.12±0.06^b

[1]	Duo Li, Zhaozhao Hao, Yanwei Chen, Yandong Nan. Correlation analysis of serum PTX3 expression and bone metastasis in non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 558-562.
[2]	Song Liu, Jinzhao Zhang, Yanyun Jia. Relationship between reduced response to pabolizumab in treatment of advanced non-small cell lung cancer and antibiotic preconditioning [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 553-557.
[3]	Xiaoyu Han, Keyu Li, Zhifei Zhao, Jianping Gao. Prognostic significance of SNHG17 overexpression for non-small cell lung cancer resection [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 543-547.
[4]	Guiping Zhang, Yonglin Qiu, Qiting Zhan, Ledong Sun. Prognostic significance of serum Ape1/Ref-1 for the radioactive lung injury in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 519-523.
[5]	Mengmeng Zhao, Jie Huang, Ronghuan Yu, Baoqing Wang. Overexpression of the small GTPase Rab32 inhibits the invasive growth of non-small cell lung cancer cells [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 512-518.
[6]	Jing Yang, Jian Fu, Yanxia Kang. Significance of plasma ctDNA T790M mutation and total metabolic tumor volume in the prognostic significance of TKIs treatment in patients with advanced EGFR mutant NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 379-384.
[7]	Haiyan Zhao, Haitao Jin, ying Kong, Ruiyuan He. Prognostic significance of plasma NGS-ctDNA in patients with advanced NSCLC treated with EGFR-TKIs [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 385-391.
[8]	Lili Bai, Yu Jiang, Liangliang Huang, Ying BAI, Min Zhang. Application of occupational therapy in postoperative rehabilitation of patients with non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 411-415.
[9]	Zhen Wang, Lu Huang, Lianqun Lang, Lu Yue. Prognostic significance of platelet and albumin/fibrinogen ratio in second-line therapy of bevacizumab for advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(01): 35-40.
[10]	Jing Li, Guoyuan Ling, Shan Jiang, Xiaoju Chen, Xiaoyun Guo. Efficacy of pemetrexed delivery via ommaya capsule implantation versus lumbar puncture in treatment of leptomeningeal metastasis of non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 128-132.
[11]	Yang Li, Kunliang Guo, Bicheng Zhan, Quanquan Hu, Yuzhen Dai. Clinicopathological and molecular genetic characteristics and programmed cell death 1 ligand 1 expression in SMARCA4-deficient non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1309-1314.
[12]	Meisi Liang, Huimin Lan, Ting Yu, Shengqiao Li. The study of plumbagin on suppressing the proliferation of non-small cell lung cancer [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(02): 120-125.
[13]	Zijian Li, Rui Wang, Yunpeng Zhong, Dixuan Zhang, Yunjuan Liang, Chao Yang, Jianxing He, Shuben Li. Clinical application of lung autotransplantation in thoracic malignancies [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 193-200.
[14]	Xunfu Zhang, Jinshan Ma, Yunlong Jiang, Tuoleheng Jianati, Changjian Hou, Silajiding Sawuti. Expression and clinicopathological significance of GATA3 protein in non-small cell lung cancer tissues [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 175-179.
[15]	Kuan Xu, Heng Zhao, Bo Ye. Interpretation of the surgical section of the 2024 first edition of the National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(02): 79-84.

Please choose a citation manager

Content to export